About Science Partnerships News Careers Contact About Vision & Mission Leadership Scientific Advisors & Founders Investors HiFiBiO Therapeutics is an emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune disease. Our Vision Pioneering curative immunotherapies for each and every patient Our Mission Unlocking the curative powers of the immune system with innovative biotherapeutics Our Strategy HiFiBiO Therapeutics is harnessing its cutting-edge single cell technologies and an open innovation partnership model to develop a sustainable pipeline of innovative immunotherapies See Our Science Leadership Team Liang Schweizer, PhD Co-founder, Chairman, Chief Executive Officer Francisco Adrian, PhD Chief Scientific Officer Luigi Manenti, MD Chief Medical Officer John Pallante Vice President, Global Head of Clinical Operations Christos Hatzis, PhD Vice President, Global Head of Clinical Pharmacogenomics Edward Rocnik, PhD Executive Director, Global Head of CMC Jinping Gan, PhD Executive Director, Global Head of Antibody Discovery and Optimization (ADO) Andreas Raue, PhD Executive Director, Global Head of Drug Intelligent Science (DIS) Rachel Yao Financial Controller Vincent Tse, MBA Senior Director of Staff and Strategy He Zhou, PhD Vice President, China General Manager Sami Ellouze Director, France General Manager Roshan Kumar, PhD Senior Director, US External Innovation Scientific Advisory Board Michael Croft, PhD Director of Scientific Affairs, Professor and Head of the Division of Immune Regulation at La Jolla Institute for Immunology Leslie Kean, MD, PhD Director of the Stem Cell Transplantation Program and Physician at Dana-Farber/Boston Children’s Cancer Center and Blood Disorders Center Aurélien Marabelle, MD, PhD Senior Medical Oncologist in the Drug Development Department and the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy Vikas P. Sukhatme, MD, ScD Dean of the Emory School of Medicine, Chief Academic Officer of Emory Healthcare and Woodruff Professor at the Emory School of Medicine Sebastian Amigorena, PhD Director of the INSERM Immunity and Cancer Lab, and head of the Immunology and Immunotherapy department at Institut Curie. Scientific Founders Andrew Griffiths, PhD Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris David Weitz, PhD Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University Bradley Bernstein, MD, PhD Professor of Pathology at the Massachusetts General Hospital and Harvard Medical School Jérôme Bibette, PhD Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI) Robert Nicol, PhD Director of the Technology Labs at the Broad Institute of MIT and Harvard Our Investors We are funded by leading early-stage venture capital firms focused on transforming patient care Open-Innovation Partnerships We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand DIS™ applications and accelerate pipeline commercialization. All our collaborations are architected for speed and driven by our scientific strategy. Learn More About Science Partnerships News Careers Contact © HiFiBiO Therapeutics, 2021. All Rights Reserved. Privacy Policy Manage cookie settings